CRSP

Crispr Therapeutics AG

A biotech company that turns the CRISPR gene-editing discovery into medicines for serious inherited diseases. Its first approved therapy, Casgevy, treats sickle cell disease and beta-thalassemia by editing a patient's own blood stem cells. Co-founded in 2013 by Emmanuelle Charpentier — one of the scientists who shared the Nobel Prize for discovering CRISPR — along with Rodger Novak and Shaun Foy, the company takes its name directly from the gene-editing system it commercializes.